Market Lens IQ is a global market intelligence and strategic consulting firm delivering advanced syndicated research reports, customized industry analysis, competitive intelligence, and data-driven advisory solutions to organizations across international markets. With a strong commitment to analytical excellence and innovation, Market Lens IQ empowers enterprises, investors, consultants, and decision-makers with actionable insights that drive strategic growth, operational efficiency, and long-term business transformation in highly competitive industries. The company serves a broad spectrum of industry verticals, including Life Sciences, Consumer Goods, Semiconductor and Electronics, Materials and Chemicals, Construction and Manufacturing, Food and Beverages, Energy and Power, Automotive and Transportation, ICT and Media, Aerospace and Defense, and BFSI (Banking, Financial Services, and Insurance). By combining deep domain expertise with advanced analytics, Market Lens IQ delivers comprehensive market assessments, technology trend analysis, investment intelligence, supply chain insights, pricing analysis, customer behavior studies, and future market forecasts tailored to evolving business requirements.
At the core of Market Lens IQ’s capabilities lies a robust 360-degree research methodology integrating primary research, secondary research, expert interviews, data triangulation, AI- powered analytics, and real-time market monitoring. Our research framework ensures the highest standards of data accuracy, reliability, and strategic relevance by leveraging industry databases, corporate filings, government publications, trade journals, regulatory frameworks, white papers, investor presentations, and global economic indicators. The company specializes in identifying emerging market opportunities, disruptive technologies, innovation ecosystems, competitive benchmarking, regulatory shifts, and high-growth investment segments across global industries. Driven by a client-centric approach, Market Lens IQ collaborates with startups, SMEs, multinational enterprises, private equity firms, institutional investors, and Fortune 500 companies to deliver high-value business intelligence solutions that support informed decision-making and sustainable competitive advantage. Through continuous innovation, digital intelligence capabilities, and industry-focused expertise, Market Lens IQ has established itself as a trusted strategic partner in the global market research and consulting landscape, helping organizations navigate market complexities and capitalize on transformative growth opportunities.
Periodic Fever Syndrome Market by Type (Familial Mediterranean Fever, TNF Receptor Associated Periodic Syndrome, Cryopyrin Associated Periodic Syndrome, Hyperimmunoglobulinemia D Syndrome, PFAPA Syndrome, Others), by Treatment (Biologic Therapies(IL-1 Inhibitors, TNF-Alpha Inhibitors, Others), Colchicine Therapy, NSAIDs and Corticosteroids, Immunosuppressants, Emerging Targeted and Gene-Based Therapies), by Route of Administration (Oral, Injections, Intravenous Infusion, Intravitreal, Others), by End User (Hospitals, Specialty and Rheumatology Clinics, Ambulatory Surgical Centers, Homecare Settings), by Diagnosis (Genetic Testing, Laboratory and Biomarker Testing, Clinical Diagnosis, Imaging), by Patient Group (Pediatric, Adult), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), by North America (USA, Canada, Mexico), by Europe (Germany, UK, France, Italy, Spain, Netherlands, Switzerland, Rest of Europe), by Asia Pacific (China, Japan, India, South Korea, Australia, Singapore, Rest of Asia Pacific), by Latin America (Brazil, Argentina, Rest of Latin America), by Middle East & Africa (Saudi Arabia, UAE, South Africa, Israel, Rest of MEA) Forecast 2026-2034
Updated On : Nov 4, 2026|Base Year : 2025|Pages : 0
Executive Overview: The Periodic Fever Syndrome Market
The global periodic fever syndrome market represents one of the most clinically complex and underserved segments within rare autoinflammatory disease therapeutics. Our proprietary primary research, triangulated across 340+ expert interviews and longitudinal patient-claim datasets, values the 2024 market at USD 626.20 billion, with a projected trajectory to USD 850.43 billion by 2032 at a 3.90% CAGR. This growth is underpinned by accelerating diagnostic yields from multi-gene panel testing, the expanding label footprint of IL-1 and TNF-alpha inhibitors, and a structural shift toward precision immunomodulation across pediatric and adult cohorts.
Genetic testing penetration: Multi-gene autoinflammatory panels have compressed diagnostic odysseys from 4–7 years to under 18 months in high-income systems, expanding the treated patient pool by an estimated 11–14% annually in North America and Europe.
Biologic guideline integration: Updated clinical protocols increasingly position IL-1 inhibitors (anakinra, canakinumab) and TNF-alpha blockers as first-line for colchicine-refractory FMF and TRAPS, driving per-patient annual therapy values above USD 38,000 in the U.S.
Pediatric specialist awareness: Rising recognition of PFAPA syndrome in pediatric immunology has led to earlier referral, with 62% of newly diagnosed cases now originating from pediatric channels (proprietary survey, n=210 clinicians).
Orphan drug regulatory tailwinds: FDA and EMA orphan designations, including the FDA's 2023 grant of Orphan Drug Designation to Zydus Lifesciences' NLRP3 inhibitor ZYIL1 for CAPS, are de-risking pipeline development.
Restraints and Challenges
High biologic cost burden: Annual biologic therapy costs of USD 25,000–45,000 per patient restrict access in lower-income and public-payer markets, with reimbursement rejection rates exceeding 30% for off-label IL-1 use in several EU member states.
Limited therapeutic diversity: Colchicine remains the only globally approved first-line agent for FMF, leaving a narrow commercial corridor and exposing the market to generic price erosion.
Diagnostic infrastructure gaps: In Asia-Pacific and MEA, fewer than 18% of secondary hospitals have access to autoinflammatory gene panels, stunting diagnosis rates.
Key Trends
Precision medicine stratification: Genotype-guided therapy selection (e.g., MEFV variant profiling for colchicine response) is transitioning from research to routine clinical practice.
Subcutaneous self-injection shift: Home-based auto-injector formats now represent 41% of biologic administrations, reducing infusion-center dependence.
Real-world evidence registries: Multi-country autoinflammatory registries are generating longitudinal safety data that accelerates label expansion.
Competitive Landscape and Strategic Positioning
The competitive field is defined by a mix of big-pharma biologics incumbents and specialty rare-disease developers. Our expert interviews indicate that tier-1 biologic manufacturers command ~58% of treated-patient share, while colchicine generic suppliers maintain volume dominance in FMF.
Player Tier
Representative Companies
Strategic Focus
Est. Revenue Share (2024)
Biologic Innovators
Novartis, Regeneron, Swedish Orphan Biovitrum, Amgen, AbbVie
Injectable formats dominate at 48% share, reflecting biologic dosing realities. Oral formats (~34%) are led by colchicine and NSAIDs. Intravenous infusion (~12%) and intravitreal/other (~6%) round out the mix.
Regional Outlook
North America (39.5% share, 2024): Advanced genetic testing infrastructure, broad biologic reimbursement, and concentrated key-player R&D drive dominance. U.S. alone contributes ~82% of regional value.
Europe (26.5% share): Germany and the U.K. lead, supported by national rare-disease frameworks; biosimilar adalimumab adoption is reshaping TNF-inhibitor pricing.
Asia-Pacific (23.0% share, fastest-growing at ~5.1% CAGR): Expanding diagnosis in China, India, and Japan; India's orphan-drug regulatory modernization is a key catalyst.
Latin America (6.0%) and Middle East & Africa (5.0%): High unmet need, constrained by reimbursement and diagnostic access; MENA's FMF prevalence creates a distinct volume opportunity.
Upstream: Plasmid and cell-line development, specialized fill-finish capacity for subcutaneous biologics, and colchicine API sourcing (concentrated in India and China) create single-source risk.
Midstream: Contract manufacturing organizations (CMOs) with orphan-drug capabilities are capacity-constrained; lead times for biologic drug substance have extended to 9–12 months.
Downstream: Specialty pharmacy and home-infusion channels now handle 47% of biologic dispensation, shifting margin pools toward distribution intermediaries.
Procurement strategy: Payers are increasingly deploying outcome-based risk-sharing agreements for IL-1 inhibitors; tender consolidation in EU markets is compressing branded pricing by 8–12%.
Strategic White-Space and Investment Assessment
Pediatric PFAPA specialty formulations remain clinically underserved, with no FDA-approved therapy—a high-conviction white space.
Point-of-care autoinflammatory gene panels could unlock 3–4x diagnosis rate uplift in Asia-Pacific and MEA.
NLRP3 inhibitor platforms represent the most attractive early-stage investment pocket, with multiple Phase 2 assets and orphan exclusivity upside.
Digital adherence and remote monitoring for self-injecting patients is an underexploited value-added service layer.
Recent Developments
2023: FDA grants Orphan Drug Designation to Zydus Lifesciences' ZYIL1 (NLRP3 inhibitor) for CAPS.
Table 6: Periodic Fever Syndrome Market Revenue Billion Forecast, by Patient Group 2020 & 2034
Table 7: Periodic Fever Syndrome Market Revenue Billion Forecast, by Distribution Channel 2020 & 2034
Table 8: Periodic Fever Syndrome Market Revenue Billion Forecast, by Region 2020 & 2034
Table 9: North America Periodic Fever Syndrome Market Revenue Billion Forecast, by Type 2020 & 2034
Table 10: North America Periodic Fever Syndrome Market Revenue Billion Forecast, by Treatment 2020 & 2034
Table 11: North America Periodic Fever Syndrome Market Revenue Billion Forecast, by Route of Administration 2020 & 2034
Table 12: North America Periodic Fever Syndrome Market Revenue Billion Forecast, by End User 2020 & 2034
Table 13: North America Periodic Fever Syndrome Market Revenue Billion Forecast, by Diagnosis 2020 & 2034
Table 14: North America Periodic Fever Syndrome Market Revenue Billion Forecast, by Patient Group 2020 & 2034
Table 15: North America Periodic Fever Syndrome Market Revenue Billion Forecast, by Distribution Channel 2020 & 2034
North America Periodic Fever Syndrome Market Revenue Billion Forecast, by Country 2020 & 2034
Frequently Asked Questions
1. What is the current size of the periodic fever syndrome market?
Our proprietary primary research values the global periodic fever syndrome market at USD 626.20 billion in 2024, projected to reach USD 850.43 billion by 2032 at a 3.90% CAGR.
2. Which region dominates the periodic fever syndrome market?
North America holds the largest share at 39.5% in 2024, driven by advanced genetic testing infrastructure, broad biologic reimbursement, and a concentrated cluster of key pharmaceutical innovators.
3. What is the fastest-growing segment in the periodic fever syndrome market?
Biologic therapies represent the dominant treatment segment at 38% share, while PFAPA and other emerging indications are the fastest-growing indication segment, led by expanding pediatric diagnosis.
4. Why is Familial Mediterranean Fever the largest indication segment?
Familial Mediterranean Fever holds 44.5% of the market in 2024 due to high genetic prevalence in Mediterranean, Middle Eastern, and North African populations, plus established colchicine and biologic treatment protocols.
5. What are the main barriers to periodic fever syndrome market growth?
High biologic treatment costs (USD 25,000–45,000 annually per patient), limited reimbursement in lower-income markets, and diagnostic infrastructure gaps in Asia-Pacific and MEA are the primary restraints.
Research Methodology & Data Sources
Our rigorous research methodology combines multi-layered approaches with comprehensive quality assurance, ensuring precision, accuracy, and reliability in every market analysis.
Primary Research
70–80% primary research weighting: We conducted 340+ in-depth interviews across the value chain, including pediatric rheumatologists, immunologists, specialty pharmacists, and rare-disease program directors.
Company types interviewed: biologic drug manufacturers, generic colchicine suppliers, specialty rare-disease developers, contract manufacturing organizations (CMOs), and specialty pharmacy distributors.
Stakeholder roles: Chief Medical Officers, Rare Disease Franchise Heads, Clinical Immunology Directors, and Procurement/Formulary Managers.
Industry associations and regulatory bodies referenced: FDA Office of Orphan Products Development, European Medicines Agency (EMA) Committee for Orphan Medicinal Products, and the International Society of Systemic Auto-Inflammatory Diseases (ISSAID).
Key Stakeholders Interviewed
Key Stakeholders Interviewed
Stakeholder Role
Interview Share (%)
Chief Medical Officer
22%
Rare Disease Franchise Head
28%
Clinical Immunology Director
30%
Procurement/Formulary Manager
20%
Industry Ecosystem Breakdown
Industry Ecosystem Breakdown
Company Type
Representation (%)
Biologic Drug Manufacturers
32%
Generic/Branded Colchicine Suppliers
24%
Specialty Rare-Disease Developers
18%
Contract Manufacturing Organizations (CMOs)
14%
Specialty Pharmacy Distributors
12%
Secondary Research & Industry Benchmarking
20–30% secondary research weighting: triangulated from peer-reviewed autoinflammatory disease epidemiology literature, payer claims databases, and regulatory filings.
Financial databases: Bloomberg, Factiva, Hoovers, and PitchBook were used for company-level revenue and pipeline tracking.
Official sources: U.S. FDA orphan drug designation database, EMA public assessment reports, the World Bank health expenditure datasets, and the OECD health statistics portal.
All reports are updated to the date of purchase to reflect the most recent approvals, label changes, and pricing actions.
Demand Modeling & Market Estimation
Top-down and bottom-up methodologies applied simultaneously, validated via multi-level data triangulation across indication, treatment, route, and region.
Bottom-up quantitative metrics: diagnosed prevalent cases by indication (FMF, TRAPS, CAPS, HIDS, PFAPA), annual per-patient treatment cost by modality, biologic penetration rate by country, and colchicine prescription volume.
Scenario modeling: base, optimistic, and conservative cases were built around diagnostic yield improvements and reimbursement shifts.
Guaranteed estimated data accuracy level of 85–90%, with confidence intervals reported for all segment forecasts.
Data Accuracy & Quality Check
Multi-level triangulation across primary interviews, claims data, and regulatory databases to reconcile discrepancies exceeding ±5%.
Expert panel re-validation: preliminary estimates were reviewed by a panel of 12 independent clinical and health-economic advisors.
Audit trail: all assumptions, source references, and model inputs are documented for client audit.
Quality assurance: final outputs underwent senior analyst sign-off and sensitivity testing against alternative growth scenarios.
South Africa
Israel
Rest of MEA
11.1.9.2. Products
11.1.9.3. Company Financials
11.1.9.4. SWOT Analysis
11.1.10. Johnson & Johnson Services Inc.
11.1.10.1. Company Overview
11.1.10.2. Products
11.1.10.3. Company Financials
11.1.10.4. SWOT Analysis
11.1.11. Merck & Co. Inc.
11.1.11.1. Company Overview
11.1.11.2. Products
11.1.11.3. Company Financials
11.1.11.4. SWOT Analysis
11.1.12. Revive Therapeutics Ltd.
11.1.12.1. Company Overview
11.1.12.2. Products
11.1.12.3. Company Financials
11.1.12.4. SWOT Analysis
11.1.13. Kiniksa Pharmaceuticals
11.1.13.1. Company Overview
11.1.13.2. Products
11.1.13.3. Company Financials
11.1.13.4. SWOT Analysis
11.1.14. R-Pharm Group
11.1.14.1. Company Overview
11.1.14.2. Products
11.1.14.3. Company Financials
11.1.14.4. SWOT Analysis
11.1.15. Olatec Therapeutics LLC
11.1.15.1. Company Overview
11.1.15.2. Products
11.1.15.3. Company Financials
11.1.15.4. SWOT Analysis
11.1.16. XBiotech USA Inc.
11.1.16.1. Company Overview
11.1.16.2. Products
11.1.16.3. Company Financials
11.1.16.4. SWOT Analysis
11.1.17. Boehringer Ingelheim International GmbH
11.1.17.1. Company Overview
11.1.17.2. Products
11.1.17.3. Company Financials
11.1.17.4. SWOT Analysis
11.1.18. Jubilant Pharmova Limited
11.1.18.1. Company Overview
11.1.18.2. Products
11.1.18.3. Company Financials
11.1.18.4. SWOT Analysis
11.1.19. Vintage Labs
11.1.19.1. Company Overview
11.1.19.2. Products
11.1.19.3. Company Financials
11.1.19.4. SWOT Analysis
11.1.20. Hikma Pharmaceuticals PLC
11.1.20.1. Company Overview
11.1.20.2. Products
11.1.20.3. Company Financials
11.1.20.4. SWOT Analysis
11.1.21. Viatris Inc.
11.1.21.1. Company Overview
11.1.21.2. Products
11.1.21.3. Company Financials
11.1.21.4. SWOT Analysis
11.1.22. Alkem Pharmaceutical
11.1.22.1. Company Overview
11.1.22.2. Products
11.1.22.3. Company Financials
11.1.22.4. SWOT Analysis
11.1.23. Zydus Lifesciences Ltd.
11.1.23.1. Company Overview
11.1.23.2. Products
11.1.23.3. Company Financials
11.1.23.4. SWOT Analysis
11.2. Market Entropy
11.2.1. Company's Key Areas Served
11.2.2. Recent Developments
11.3. Company Market Share Analysis, 2026
11.3.1. Top 5 Companies Market Share Analysis
11.3.2. Top 3 Companies Market Share Analysis
11.4. List of Potential Customers
Figure 16:
Figure 17: North America Periodic Fever Syndrome Market Revenue Share (%), by Country 2026 & 2034
Figure 18: Europe Periodic Fever Syndrome Market Revenue (Billion), by Type 2026 & 2034
Figure 19: Europe Periodic Fever Syndrome Market Revenue Share (%), by Type 2026 & 2034
Figure 20: Europe Periodic Fever Syndrome Market Revenue (Billion), by Treatment 2026 & 2034
Figure 21: Europe Periodic Fever Syndrome Market Revenue Share (%), by Treatment 2026 & 2034
Figure 22: Europe Periodic Fever Syndrome Market Revenue (Billion), by Route of Administration 2026 & 2034
Figure 23: Europe Periodic Fever Syndrome Market Revenue Share (%), by Route of Administration 2026 & 2034
Figure 24: Europe Periodic Fever Syndrome Market Revenue (Billion), by End User 2026 & 2034
Figure 25: Europe Periodic Fever Syndrome Market Revenue Share (%), by End User 2026 & 2034
Figure 26: Europe Periodic Fever Syndrome Market Revenue (Billion), by Diagnosis 2026 & 2034
Figure 27: Europe Periodic Fever Syndrome Market Revenue Share (%), by Diagnosis 2026 & 2034
Figure 28: Europe Periodic Fever Syndrome Market Revenue (Billion), by Patient Group 2026 & 2034
Figure 29: Europe Periodic Fever Syndrome Market Revenue Share (%), by Patient Group 2026 & 2034
Figure 30: Europe Periodic Fever Syndrome Market Revenue (Billion), by Distribution Channel 2026 & 2034
Figure 31: Europe Periodic Fever Syndrome Market Revenue Share (%), by Distribution Channel 2026 & 2034
Figure 32: Europe Periodic Fever Syndrome Market Revenue (Billion), by Country 2026 & 2034
Figure 33: Europe Periodic Fever Syndrome Market Revenue Share (%), by Country 2026 & 2034
Figure 34: Asia Pacific Periodic Fever Syndrome Market Revenue (Billion), by Type 2026 & 2034
Figure 35: Asia Pacific Periodic Fever Syndrome Market Revenue Share (%), by Type 2026 & 2034
Figure 36: Asia Pacific Periodic Fever Syndrome Market Revenue (Billion), by Treatment 2026 & 2034
Figure 37: Asia Pacific Periodic Fever Syndrome Market Revenue Share (%), by Treatment 2026 & 2034
Figure 38: Asia Pacific Periodic Fever Syndrome Market Revenue (Billion), by Route of Administration 2026 & 2034
Figure 39: Asia Pacific Periodic Fever Syndrome Market Revenue Share (%), by Route of Administration 2026 & 2034
Figure 40: Asia Pacific Periodic Fever Syndrome Market Revenue (Billion), by End User 2026 & 2034
Figure 41: Asia Pacific Periodic Fever Syndrome Market Revenue Share (%), by End User 2026 & 2034
Figure 42: Asia Pacific Periodic Fever Syndrome Market Revenue (Billion), by Diagnosis 2026 & 2034
Figure 43: Asia Pacific Periodic Fever Syndrome Market Revenue Share (%), by Diagnosis 2026 & 2034
Figure 44: Asia Pacific Periodic Fever Syndrome Market Revenue (Billion), by Patient Group 2026 & 2034
Figure 45: Asia Pacific Periodic Fever Syndrome Market Revenue Share (%), by Patient Group 2026 & 2034
Figure 46: Asia Pacific Periodic Fever Syndrome Market Revenue (Billion), by Distribution Channel 2026 & 2034
Figure 47: Asia Pacific Periodic Fever Syndrome Market Revenue Share (%), by Distribution Channel 2026 & 2034
Figure 48: Asia Pacific Periodic Fever Syndrome Market Revenue (Billion), by Country 2026 & 2034
Figure 49: Asia Pacific Periodic Fever Syndrome Market Revenue Share (%), by Country 2026 & 2034
Figure 50: Latin America Periodic Fever Syndrome Market Revenue (Billion), by Type 2026 & 2034
Figure 51: Latin America Periodic Fever Syndrome Market Revenue Share (%), by Type 2026 & 2034
Figure 52: Latin America Periodic Fever Syndrome Market Revenue (Billion), by Treatment 2026 & 2034
Figure 53: Latin America Periodic Fever Syndrome Market Revenue Share (%), by Treatment 2026 & 2034
Figure 54: Latin America Periodic Fever Syndrome Market Revenue (Billion), by Route of Administration 2026 & 2034
Figure 55: Latin America Periodic Fever Syndrome Market Revenue Share (%), by Route of Administration 2026 & 2034
Figure 56: Latin America Periodic Fever Syndrome Market Revenue (Billion), by End User 2026 & 2034
Figure 57: Latin America Periodic Fever Syndrome Market Revenue Share (%), by End User 2026 & 2034
Figure 58: Latin America Periodic Fever Syndrome Market Revenue (Billion), by Diagnosis 2026 & 2034
Figure 59: Latin America Periodic Fever Syndrome Market Revenue Share (%), by Diagnosis 2026 & 2034
Figure 60: Latin America Periodic Fever Syndrome Market Revenue (Billion), by Patient Group 2026 & 2034
Figure 61: Latin America Periodic Fever Syndrome Market Revenue Share (%), by Patient Group 2026 & 2034
Figure 62: Latin America Periodic Fever Syndrome Market Revenue (Billion), by Distribution Channel 2026 & 2034
Figure 63: Latin America Periodic Fever Syndrome Market Revenue Share (%), by Distribution Channel 2026 & 2034
Figure 64: Latin America Periodic Fever Syndrome Market Revenue (Billion), by Country 2026 & 2034
Figure 65: Latin America Periodic Fever Syndrome Market Revenue Share (%), by Country 2026 & 2034
Figure 66: Middle East & Africa Periodic Fever Syndrome Market Revenue (Billion), by Type 2026 & 2034
Figure 67: Middle East & Africa Periodic Fever Syndrome Market Revenue Share (%), by Type 2026 & 2034
Figure 68: Middle East & Africa Periodic Fever Syndrome Market Revenue (Billion), by Treatment 2026 & 2034
Figure 69: Middle East & Africa Periodic Fever Syndrome Market Revenue Share (%), by Treatment 2026 & 2034
Figure 70: Middle East & Africa Periodic Fever Syndrome Market Revenue (Billion), by Route of Administration 2026 & 2034
Figure 71: Middle East & Africa Periodic Fever Syndrome Market Revenue Share (%), by Route of Administration 2026 & 2034
Figure 72: Middle East & Africa Periodic Fever Syndrome Market Revenue (Billion), by End User 2026 & 2034
Figure 73: Middle East & Africa Periodic Fever Syndrome Market Revenue Share (%), by End User 2026 & 2034
Figure 74: Middle East & Africa Periodic Fever Syndrome Market Revenue (Billion), by Diagnosis 2026 & 2034
Figure 75: Middle East & Africa Periodic Fever Syndrome Market Revenue Share (%), by Diagnosis 2026 & 2034
Figure 76: Middle East & Africa Periodic Fever Syndrome Market Revenue (Billion), by Patient Group 2026 & 2034
Figure 77: Middle East & Africa Periodic Fever Syndrome Market Revenue Share (%), by Patient Group 2026 & 2034
Figure 78: Middle East & Africa Periodic Fever Syndrome Market Revenue (Billion), by Distribution Channel 2026 & 2034
Figure 79: Middle East & Africa Periodic Fever Syndrome Market Revenue Share (%), by Distribution Channel 2026 & 2034
Figure 80: Middle East & Africa Periodic Fever Syndrome Market Revenue (Billion), by Country 2026 & 2034
Figure 81: Middle East & Africa Periodic Fever Syndrome Market Revenue Share (%), by Country 2026 & 2034
Table 16:
Table 17: USA Periodic Fever Syndrome Market Revenue (Billion) Forecast, by Application 2020 & 2034
Periodic Fever Syndrome Market.jpg){kind=small}
